Related by context. All words. (Click for frequent words.) 70 cell Lymphoma PTCL 66 cell acute lymphoblastic 64 cell lymphomas 64 refractory peripheral T 63 relapsed refractory multiple myeloma 62 cutaneous T cell 62 cell lymphoma CTCL 62 cell lymphoma ALCL 61 lymphoma CTCL 61 IV administered darinaparsin 61 cell lymphoma 60 leukemia CLL 60 leukemia AML 60 Cutaneous T 60 hepatocellular carcinoma HCC 60 lymphocytosis 60 cutaneous T 59 leukemia ALL 59 metastatic renal cell carcinoma 59 refractory multiple myeloma 58 recurrent GBM 58 mRCC 58 recurrent glioblastoma multiforme 58 pheochromocytoma 58 tumors GIST 58 zanolimumab 58 cell lymphoblastic lymphoma 58 romidepsin 58 B CLL 58 metastatic GIST 58 T Cell Lymphoma 57 myelofibrosis MF 57 metastatic malignant melanoma 57 refractory Hodgkin lymphoma 57 metastatic malignant 57 castrate resistant prostate cancer 57 recurrent glioblastoma 57 grade cervical intraepithelial 57 NEUVENGE 57 recurrent NSCLC 57 systemic anaplastic large 57 solid tumors 57 Acute Myeloid Leukemia AML 56 allogeneic bone marrow 56 chronic lymphocytic leukemia CLL 56 refractory metastatic colorectal cancer 56 relapsed refractory 56 Lymphomas 56 cell malignancies 56 Neuvenge 56 unresectable 56 HBeAg negative 56 refractory cutaneous T 56 MGd 56 tumor xenograft models 56 relapsed multiple myeloma 56 recurrent malignant glioma 56 de novo AML 56 myeloproliferative diseases 56 myelodysplastic syndrome MDS 56 follicular lymphoma FL 56 refractory acute myeloid 55 hepatocellular carcinoma 55 galiximab 55 lupus nephritis 55 CTCL 55 Sezary syndrome 55 intravenous belinostat 55 gastrointestinal stromal tumors GIST 55 huN# DM1 55 HBeAg positive 55 aHUS 55 lymphoblastic leukemia 55 severe neutropenia 55 atypical Hemolytic Uremic Syndrome 55 MALT lymphoma 55 Glioblastoma Multiforme 55 HBeAg negative patients 55 bone metastasis 55 cervical carcinoma 55 systemic lupus erythematosus SLE 55 TMC# C# 55 myeloid 55 refractory chronic lymphocytic 55 cetuximab Erbitux R 55 gastric carcinoma 55 multiple myeloma MM 55 CD# + [001] 55 pulmonary metastases 55 non metastatic osteosarcoma 55 hepatitis C HCV 55 alpha folate receptor 55 Chronic Lymphocytic Leukemia 55 essential thrombocythemia 55 gastrointestinal stromal tumor GIST 55 leukemia CML 55 hematological malignancies 55 refractory AML 54 phase IIb clinical 54 Alemtuzumab 54 erlotinib Tarceva ® 54 chronic eosinophilic leukemia 54 Myelodysplastic Syndrome MDS 54 rALLy 54 Leukemias 54 thymoma 54 unresectable recurrent 54 metastatic neuroendocrine tumors 54 Enzastaurin 54 ovarian carcinoma 54 Telintra 54 acute coronary syndromes ACS 54 lymphoid malignancies 54 cholangiocarcinoma 54 soft tissue sarcomas 54 HCV SPRINT 54 symptomatic BPH 54 hematologic disorders 54 metastatic gastric 54 Relapsed Refractory 54 non squamous NSCLC 54 HGS ETR2 54 Aplidin 54 Hodgkin lymphoma HL 54 platinum refractory 54 Phase IIIb clinical 54 paraganglioma 54 malignant fibrous histiocytoma 54 rALLy clinical trial 54 Kit CD# positive 54 pancreatic carcinoma 54 TELCYTA 54 K ras mutations 54 tumor lysis syndrome 54 T2DM 54 acute myelogenous leukemia AML 54 gastrointestinal stromal tumors 54 BARACLUDE ® 54 GISTs 54 randomized Phase IIb 54 relapsing remitting MS RRMS 54 KRAS wild 54 GvHD 54 CLL SLL 53 heavily pretreated 53 imatinib resistant 53 situ CIS 53 Epratuzumab 53 myelofibrosis 53 metastatic colorectal 53 IMGN# 53 Fibrillex TM 53 Tavocept 53 Romiplostim 53 hypereosinophilic syndrome 53 extranodal 53 BR.# 53 stage IIIB 53 Acute Myelogenous Leukemia AML 53 dasatinib Sprycel ® 53 ISTODAX 53 familial amyloidotic polyneuropathy FAP 53 mycophenolate mofetil 53 NMIBC 53 Follicular Lymphoma 53 Vicinium TM 53 medullary thyroid cancer 53 BAY #-# 53 assessing T DM1 53 acute leukemias 53 mCRC 53 CYT# potent vascular disrupting 53 pancreatic adenocarcinoma 53 receptor tyrosine kinase inhibitor 53 DAPT 53 liver metastases 53 bendamustine 53 visilizumab 53 relapsing multiple sclerosis 53 autoantibody positive 53 Cell Non Hodgkin 53 refractory CTCL 53 carboplatin paclitaxel 53 Fludarabine 53 systemic lupus erythematosus 53 Blinatumomab 53 azacitidine 53 immune thrombocytopenic purpura 53 Phase Ib II 53 leukemia APL 53 IV metastatic melanoma 53 allogeneic stem cell 53 Brentuximab Vedotin SGN 53 leukocytosis 53 PNP inhibitor 53 HER2 positive cancers 53 relapsed acute myelogenous 53 axitinib 53 interferon alfa 2a 53 SCCHN 53 peritoneal carcinomatosis 53 vWD 53 metastatic melanoma 53 fallopian tube cancers 53 small lymphocytic lymphoma 53 nonalcoholic steatohepatitis NASH 53 pT3 53 basal cell carcinoma BCC 53 hepatocellular carcinomas 53 refractory chronic myeloid 53 AEG# 53 Pharmacokinetics PK 52 phase IIb trial 52 huC# DM4 52 TASKi2 52 Cell Lymphoma 52 myelodysplastic syndromes MDS 52 cell chronic lymphocytic 52 depsipeptide 52 keloid scarring 52 hematologic malignancies 52 enzastaurin 52 castration resistant prostate cancer 52 recurrent glioma 52 elacytarabine 52 mTOR inhibitor 52 heavily pretreated patients 52 ADPKD 52 metastatic RCC 52 myelodysplastic syndromes 52 biliary tract cancer 52 HuMax CD4 52 Doxil ® 52 systemic fungal infections 52 squamous 52 renal cell carcinoma 52 Phase #b/#a clinical 52 breast carcinomas 52 acute myeloid 52 ZYBRESTAT fosbretabulin 52 metastatic bladder 52 lymphomas 52 Phase Ib clinical 52 investigational monoclonal antibody 52 nonmetastatic 52 glufosfamide 52 FOLFOX6 52 chronic HBV infection 52 Pemetrexed 52 APOPTONE 52 idiopathic thrombocytopenic purpura ITP 52 Mantle Cell Lymphoma 52 haematologic 52 pertuzumab 52 Tamibarotene 52 Diffuse Large B 52 recurrent ovarian cancer 52 epithelioid 52 Chronic Lymphocytic Leukemia CLL 52 relapsed SCLC 52 tocilizumab 52 Bortezomib 52 AA Amyloidosis 52 paroxysmal nocturnal hemoglobinuria PNH 52 colorectal liver metastases 52 adecatumumab 52 decitabine 52 hepatitis C genotype 52 VELCADE melphalan 52 alvespimycin 52 Hepatocellular Carcinoma HCC 52 forodesine 52 PNET 52 dasatinib Sprycel 52 chronic GVHD 52 decompensated liver disease 52 chronic myeloid leukemia CML 52 skeletal metastases 52 OncoVEX GM CSF 52 relapsing remitting multiple sclerosis 52 lymphoid blast 52 TORISEL 52 placebo controlled clinical 52 refractory NSCLC 52 Amrubicin 52 Waldenstrom macroglobulinemia 52 blinatumomab 52 cytopenias 52 Fludara 52 myeloproliferative disorder 52 macroalbuminuria 52 sunitinib Sutent 52 cutaneous melanoma 52 imatinib Gleevec ® 52 Clolar 52 oral ridaforolimus 52 bone marrow lymph nodes 52 tanespimycin 52 immunomodulatory therapy 52 EVEREST II 52 pediatric malignancies 52 refractory systemic anaplastic 52 advanced hepatocellular carcinoma 52 IV NSCLC 52 Chronic lymphocytic leukemia 52 relapsed Acute Myeloid 52 refractory CLL 52 imatinib Gleevec 52 relapsing remitting 52 papillary 52 dacetuzumab 52 dose escalation clinical 52 glioblastoma multiforme GBM 52 bevacizumab Avastin ® 52 lymphoid 52 HER2 positive metastatic breast 52 metastatic colorectal cancer 52 sunitinib Sutent ® 52 androgen independent 52 non metastatic resectable 52 colorectal adenocarcinoma 52 Phase 2b trial 52 metastatic HRPC 52 resectable 52 ROCKET AF 52 lobular carcinoma 52 stage IIIb IV 52 advanced carcinoid 52 T#I [002] 52 hypercalcemia 52 lymphocytic leukemia 52 sunitinib 52 unresectable tumors 51 Malignant Melanoma 51 imatinib mesylate 51 Folotyn 51 sunitinib malate 51 CD# monoclonal antibody 51 Diabetic Macular Edema 51 gefitinib Iressa 51 EGFR mutation positive 51 CMV disease 51 haematopoietic 51 osteoclast 51 Genasense ® 51 relapsed mantle 51 Xanafide 51 EDEMA3 51 pan HDAC inhibitor 51 relapsed MM 51 Pralatrexate 51 AA amyloidosis 51 Advanced Renal Cell 51 neoadjuvant 51 refractory anaplastic astrocytoma 51 rheumatoid arthritis RA psoriatic 51 Ceflatonin 51 crizotinib PF # 51 heterozygous FH 51 mixed dyslipidemia 51 purpura ITP 51 PROCRIT ® 51 HCV RESPOND 2 51 metastatic renal cell 51 HSCT 51 non splenectomized 51 metastatic pancreatic 51 myelofibrosis polycythemia vera 51 alefacept 51 BRAF mutation 51 allogeneic transplants 51 suppressor cells 51 secondary hyperparathyroidism 51 Traficet EN 51 sarcomas 51 sorafenib Nexavar 51 intravesical therapy 51 IV melanoma 51 hematopoietic cell 51 vinorelbine 51 orthotopic 51 leukaemias 51 EGFR HER2 51 haematologic malignancies 51 antibody MAb 51 relapsed leukemia 51 FTY# 51 prospectively defined 51 pediatric glioma 51 ara C 51 Acute myeloid leukemia 51 Cloretazine ® 51 ARCOXIA 51 resistant ovarian cancer 51 prostate carcinoma 51 cetuximab Erbitux ® 51 LHRH receptor positive 51 urothelial carcinoma 51 posaconazole 51 HCV genotypes 51 neoplasia 51 lymphadenopathy 51 polycythemia vera 51 Cloretazine R VNP#M 51 node metastases 51 registrational trial 51 AQ4N 51 ENESTnd 51 SNT MC# 51 CD# + [002] 51 HoFH 51 systemic ALCL 51 epithelial tumors 51 lymphopenia 51 anticancer therapy 51 mCRC patients 51 ankylosing spondylitis AS 51 lintuzumab 51 syngeneic 51 cirrhotic 51 NSABP 51 natalizumab 51 cells hESCs 51 lupus erythematosus 51 subependymal giant cell 51 acute ischemic stroke 51 neuroendocrine tumors 51 myeloproliferative disorders 51 malignant neoplasms 51 MabCampath 51 pediatric acute lymphoblastic 51 HCV infected 51 Phase IIa trial 51 Lenalidomide 51 hypercholesterolemic patients 51 opioid induced constipation OIC 51 micrometastases 51 ACZ# 51 radiation sensitizer 51 rFVIIa 51 Azedra 51 targeting CD# 51 Phase IIb trials 51 recurrent glioblastoma multiforme GBM 51 low dose cytarabine 51 eculizumab 51 BRIM2 51 PCa 51 cancer mCRC 51 hematological malignancy 51 Glioblastoma multiforme GBM 51 Glioma 51 Gleevec resistant 51 EOquin TM 51 vidofludimus 51 satraplatin Phase 51 fungoides 51 prostate cancer HRPC 51 Stedivaze 51 chronic myeloid 51 dasatinib 51 pancreatic neuroendocrine tumors 51 StemEx 51 STRIDE PD 51 Tarceva TM 51 pancreatic islet cell 51 carcinoid tumors 51 Telcyta 51 malignant pleural mesothelioma 51 nonsmall cell lung cancer 51 Dasatinib 51 Trastuzumab 51 histological subtype 51 Metastatic 51 YONDELIS 51 gastrointestinal stromal tumor 51 FLT3 51 multicentre randomized 51 osteosarcomas 51 EGFr 51 canakinumab 51 ixabepilone 51 metastatic castration resistant 51 Cytoxan 51 B lymphocytes 50 calcineurin inhibitors 50 prostate cancer CaP 50 Phase #/#a trial 50 CTAP# Capsules 50 curative resection 50 DAVANAT 50 antiangiogenic therapy 50 refractory indolent non 50 Phase III pivotal 50 receiving VICTRELIS 50 endometrioid 50 Aflibercept 50 Follicular lymphoma 50 adenocarcinomas 50 Zolinza 50 ependymoma 50 metastatic hormone refractory 50 hepatocellular cancer 50 fosbretabulin 50 TELINTRA 50 TEMODAL 50 Carcinoid tumors 50 IMC A# 50 pediatric Crohn disease 50 SEPET TM 50 Multiple Myeloma MM 50 seminoma 50 MEND CABG 50 SPIRIT III 50 hepatorenal syndrome 50 novel VDA molecule 50 COMFORT II 50 PCNSL 50 de novo kidney transplant 50 Severe Primary IGFD 50 smoldering myeloma 50 lymphatic tissue 50 pralatrexate 50 renal cell carcinomas 50 acute GvHD 50 luteinizing hormone releasing 50 neoplasias 50 cilengitide 50 squamous cell carcinoma SCC 50 essential thrombocythemia ET 50 superficial bladder cancer 50 lung carcinomas 50 common hematologic malignancy 50 EpCAM 50 evaluating Xcytrin 50 EOquin 50 myeloid cells 50 cediranib 50 GAMMAGARD 50 INCB# [003] 50 hormone refractory prostate cancer 50 Gleevec imatinib mesylate 50 HIF PHI 50 malignant neoplasm 50 Nexavar sorafenib 50 VEGFR2 50 SHPT 50 paclitaxel eluting stents 50 histone deacetylase HDAC inhibitor 50 BRAF mutations 50 VZV 50 renal tumors 50 GEM OS1 50 Myelofibrosis 50 tyrosine kinase inhibitors 50 EDEMA4 50 CALGB 50 relapsed AML 50 seropositive patients 50 papillary renal cell carcinoma 50 Phase IIb trial 50 neoplasm 50 efalizumab 50 advanced metastatic prostate 50 vWF 50 cancer neuroendocrine tumor 50 acute humoral rejection 50 effector T 50 mucinous 50 pemphigus vulgaris 50 octreotide implant 50 Proxinium TM 50 Pegasys ® 50 myeloproliferative neoplasms 50 pegfilgrastim 50 oral FTY# 50 refractory gout 50 colon carcinoma 50 BRAF inhibitor 50 Golimumab 50 invasive candidiasis 50 dose cohorts 50 RG# [001] 50 proteasome inhibitor 50 metastatic kidney 50 FOLFIRI alone 50 Folfox 50 grade glioma 50 Marqibo 50 sorafenib tablets 50 budesonide foam 50 evaluating REVLIMID 50 anti angiogenic therapy 50 ADVEXIN 50 non squamous 50 TroVax ® 50 chronic ITP 50 Neulasta ® 50 chlorambucil 50 Phase Ib IIa 50 FOLPI 50 mertansine 50 colorectal cancer CRC 50 chemoresistant 50 indolent NHL 50 Dacogen injection 50 hepatic metastases 50 Sudhir Agrawal D.Phil 50 Prestara 50 RRMS patients 50 MAGE A3 ASCI 50 investigational therapies 50 trabectedin 50 TACI Ig 50 Daclizumab 50 pegylated liposomal doxorubicin 50 anti leukemic 50 lymphoma subtypes 50 Soft Tissue Sarcoma 50 metastatic CRC 50 INCB# [001] 50 paclitaxel cisplatin 50 hypoxia inducible factor 50 Wegener granulomatosis 50 gemcitabine carboplatin 50 evaluable subjects 50 carfilzomib 50 tipranavir ritonavir 50 temsirolimus 50 Plicera 50 PsA 50 TRANSFORMS 50 Romidepsin 50 untreated multiple myeloma 50 Etanercept 50 Torisel 50 PRIMO CABG 50 lymphocytes 50 hereditary angioedema HAE 50 fallopian tube carcinoma 50 multicenter randomized controlled 50 B Cell Lymphoma 50 riociguat 50 LymphoStat B belimumab 50 PNH patients 50 G CSF 50 SCH # 50 pleomorphic 50 cytokine refractory 50 cytotoxic chemotherapy 50 AP# [003] 50 homozygous familial hypercholesterolemia 50 eosinophilic asthma 50 docetaxel Taxotere ® 50 advanced metastatic renal 50 unresectable stage 50 refractory myeloma 50 Hodgkin lymphoma NHL 50 fludarabine 50 EGFR TKI 50 ILLUMINATE 50 treatment naive genotype 50 Herceptin trastuzumab 50 atherothrombotic events 50 refractory HL 50 atypical hemolytic uremic syndrome 50 T#I mutant 50 unique alkylating agent 50 metastatic lung cancer 50 adjuvant colon cancer 50 lymphoproliferative disorders 50 macroglobulinemia 50 NO# [002] 50 colorectal carcinoma 50 sorafenib 50 tigecycline 49 BRIM3 49 nucleoside analog 49 clofarabine 49 bladder carcinoma 49 NATRECOR R 49 nab paclitaxel 49 perifosine 49 Cloretazine 49 Phase Ib 49 olaparib 49 registrational 49 SPRYCEL ® 49 Chronic Myeloid Leukemia 49 MPS IVA 49 R sorafenib tablets 49 CEQ# 49 HuMax EGFr 49 erlotinib 49 B lymphocyte 49 eltrombopag 49 EFAPROXYN 49 Hsp# Inhibitor 49 follicular Non Hodgkin 49 Alocrest 49 Omacetaxine 49 anti EGFR antibody 49 Newly Diagnosed Multiple Myeloma 49 GRN#L 49 tyrosine kinase inhibitor 49 trastuzumab Herceptin ® 49 primary hypercholesterolemia 49 prostate carcinomas 49 Targretin capsules 49 Acute lymphoblastic leukemia 49 Randomized Phase 49 chronic ITP patients 49 Gemzar ® 49 EGFR expressing 49 GVHD 49 IMA# 49 RhuDex ® 49 elotuzumab 49 NSABP B 49 carcinoid 49 mycosis fungoides 49 Vectibix 49 ALCL 49 IRESSA 49 Phase Ib study 49 ZACTIMA 49 Elotuzumab 49 Anaplastic large 49 metastatic tumors 49 peripheral blood mononuclear 49 NOMID 49 basal cell nevus syndrome 49 PXD# 49 basiliximab 49 VEGFR2 inhibitor 49 Genasense 49 Acute myeloid leukemia AML 49 myeloproliferative 49 KRAS mutation 49 Phase 2b clinical 49 uPA 49 candidemia 49 polycythemia vera PV 49 interferon alfa 2b 49 Acute Myeloid Leukaemia AML 49 FOLOTYN 49 nonmyeloablative 49 rituximab refractory 49 K ras 49 Irinotecan 49 HBeAg positive patients 49 renal disease 49 mediated immunity 49 Ceflatonin R 49 NSCLC 49 myelosuppression 49 angiographic outcomes 49 Gliomas 49 Kaposi sarcoma 49 vandetanib 49 Castration Resistant Prostate Cancer 49 HuLuc# 49 chronic HCV 49 sodium glucose cotransporter 49 recurrent VTE 49 acute myeloid leukemia AML 49 bronchogenic carcinoma 49 MAPK pathway 49 CMV infection 49 Myelodysplastic syndromes MDS 49 Metastatic Colorectal Cancer 49 lymphoid tissue 49 grade gliomas 49 colorectal tumors 49 Zarnestra 49 PKC# 49 NF kB pathway 49 CHOP chemotherapy 49 T#I mutation 49 Hedgehog Pathway Inhibitor 49 metastatic colorectal carcinoma 49 Li Fraumeni Syndrome 49 TNF antagonist 49 oligodendroglioma 49 immunomodulator 49 dacarbazine 49 adalimumab Humira 49 thalidomide Thalomid 49 gouty arthritis 49 confirmatory Phase III 49 randomized multicenter trial 49 extracranial 49 Vidaza azacitidine 49 GW# [003] 49 lenalidomide Revlimid R 49 Perifosine 49 sarcoma 49 Imprime PGG 49 myeloma cells 49 malignancies 49 hematopoietic progenitor cells 49 CYPHER R Sirolimus eluting 49 APTIVUS r 49 mitogenic 49 kidney urologic 49 peginterferon alfa 2b 49 docetaxel Taxotere 49 prostate pancreatic 49 prostate tumor 49 Rituxan rituximab 49 cerebrospinal fluid CSF 49 orally administered inhibitor 49 allogeneic 49 IAP inhibitor 49 multicenter clinical 49 Augment Injectable 49 ritonavir boosted 49 prostate cancer AIPC 49 autoimmune hemolytic anemia 49 bevacizumab Avastin 49 imatinib therapy 49 phase Ib 49 PREZISTA r 49 quantitative computed tomography 49 prostate cancer PCa 49 demyelinating 49 erythropoietic 49 MERLIN TIMI 49 pancreatic NET 49 neoadjuvant therapy 49 PTLD 49 dexamethasone Decadron 49 active comparator 49 indolent follicular non 49 dose escalation phase 49 follicular lymphomas 49 gastric cancers 49 SSc patients 49 duodenal ulcer 49 oral antidiabetic agents 49 refractory PTCL 49 Toxicities 49 TAXUS IV 49 histologically confirmed 49 cetuximab Erbitux 49 liver transplant recipients 49 Phase 2b study 49 ON #.Na 49 chronic lymphocytic leukemia 49 iclaprim 49 telaprevir dosed 49 neratinib 49 nucleoside naive 49 Chronic lymphocytic leukemia CLL 49 ofatumumab HuMax CD# 49 UVIDEM 49 noninfectious uveitis 49 Median PFS 49 metaglidasen 49 HRPC 49 EGFR mutation 49 dose cohort 49 mTOR inhibitors 49 dacarbazine DTIC 49 Everolimus 49 medically inoperable 49 Omnitarg 49 Ophena TM 49 HBeAg seroconversion 49 Apaziquone 49 oligodendrogliomas 49 CLARITY study 49 Chronic myeloid leukemia CML 49 Sym# 49 non Hodgkin lymphomas 49 pazopanib 49 pro angiogenic 49 neoplastic diseases 49 Refractory Hodgkin Lymphoma 49 placebo controlled Phase III 49 octreotide 49 relapsed CLL 49 progressive PsA 49 dosing cohorts 49 idiopathic pulmonary fibrosis IPF 48 Glioblastomas 48 FOLFOX 48 chronic plaque psoriasis 48 VEGF inhibitors 48 Treanda 48 follicular NHL 48 chronic myelogenous leukemia CML 48 TACE 48 CD# expressing 48 evaluating tivozanib 48 Symadex 48 opioid receptor antagonist 48 mcg albinterferon alfa 2b 48 rituximab 48 medulloblastoma 48 partial onset seizures 48 belinostat 48 non hodgkin lymphoma 48 phase IIa clinical 48 astrocytomas 48 DLBCL 48 relapsed ovarian cancer 48 FAME Study 48 Faslodex 48 achieved PASI 48 diabetic nephropathy 48 chronic HCV infection 48 neoplasms 48 Rheumatoid Arthritis RA 48 Myelodysplastic Syndrome 48 refractory DLBCL 48 cytogenetic responses 48 humanized monoclonal antibody 48 irinotecan containing 48 Evoltra ® 48 idarubicin 48 PDGFR alpha 48 hormone refractory 48 PROSTVAC VF 48 differentiated thyroid 48 FluCAM 48 velaglucerase alfa 48 plus gemcitabine 48 T DM1 48 romiplostim 48 MGUS 48 gastrointestinal stromal tumors GISTs 48 liposomal doxorubicin 48 Phase IIb clinical 48 peripheral 48 refractory colorectal cancer 48 prostate cancer mCRPC 48 anaplastic thyroid cancer 48 KRAS status 48 ACTEMRA TM 48 Relapsed 48 ENMD # 48 fibrotic disease 48 VADT 48 lymphoid cells 48 randomized Phase III 48 doxorubicin cyclophosphamide 48 hA# 48 schwannomas 48 HBeAg negative chronic hepatitis 48 MLL AF9 48 ibritumomab tiuxetan 48 breast carcinoma 48 palifosfamide 48 Mylotarg 48 chemotherapeutic agent 48 gastric adenocarcinoma 48 Flu Cy 48 octreotide LAR 48 splenectomized patients 48 capecitabine Xeloda 48 EGFR inhibitors 48 ovarian lung 48 Acute Myelogenous Leukemia 48 placebo controlled Phase 48 glioblastoma 48 XL# XL# XL# 48 valopicitabine 48 post herpetic neuralgia 48 ToGA 48 antiretroviral naïve 48 Acute Myeloid Leukemia 48 HbF 48 ganetespib 48 biologic therapy 48 lumiliximab 48 Chronic Myelogenous Leukemia 48 Glioblastoma Multiforme GBM 48 aflibercept VEGF Trap 48 invasive aspergillosis 48 ZYBRESTAT 48 postoperative pathology 48 localized renal 48 juvenile idiopathic arthritis JIA 48 Virulizin ® 48 tumor antigen 48 TG# [001] 48 leukemic stem cells 48 stage IIIA 48 nonmelanoma skin cancers 48 haematological malignancies 48 tamibarotene 48 GOUT 48 tumor metastases 48 HER2 overexpression 48 Beta catenin pathway 48 HuCNS SC cells 48 lymphocytic 48 refractory metastatic